94 related articles for article (PubMed ID: 19956878)
21. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.
Croci T; Landi M; Galzin AM; Marini P
Br J Pharmacol; 2003 Sep; 140(1):115-22. PubMed ID: 12967941
[TBL] [Abstract][Full Text] [Related]
22. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.
Santoro A; Pisanti S; Grimaldi C; Izzo AA; Borrelli F; Proto MC; Malfitano AM; Gazzerro P; Laezza C; Bifulco M
Int J Cancer; 2009 Sep; 125(5):996-1003. PubMed ID: 19479993
[TBL] [Abstract][Full Text] [Related]
23. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Cinar R; Szücs M
J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
[TBL] [Abstract][Full Text] [Related]
24. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
25. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
Xu JM; Azzariti A; Colucci G; Paradiso A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):442-8. PubMed ID: 13680161
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
27. Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats.
Wakley AA; Rasmussen EB
Pharmacol Biochem Behav; 2009 Nov; 94(1):30-6. PubMed ID: 19602424
[TBL] [Abstract][Full Text] [Related]
28. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Griebel G; Stemmelin J; Scatton B
Biol Psychiatry; 2005 Feb; 57(3):261-7. PubMed ID: 15691527
[TBL] [Abstract][Full Text] [Related]
29. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.
Horder J; Cowen PJ; Di Simplicio M; Browning M; Harmer CJ
Psychopharmacology (Berl); 2009 Jul; 205(1):85-91. PubMed ID: 19337726
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.
Xi ZX; Spiller K; Pak AC; Gilbert J; Dillon C; Li X; Peng XQ; Gardner EL
Neuropsychopharmacology; 2008 Jun; 33(7):1735-45. PubMed ID: 17728698
[TBL] [Abstract][Full Text] [Related]
31. The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats.
Rutkowska M
Acta Pol Pharm; 2004; 61(5):401-3. PubMed ID: 15747698
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Voigt W; Pickan V; Pfeiffer C; Mueller T; Simon H; Arnold D
Onkologie; 2005 Oct; 28(10):482-8. PubMed ID: 16160394
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
35. Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
Liu Y; Xiao E; Yuan L; Li G
DNA Cell Biol; 2014 Jul; 33(7):418-25. PubMed ID: 24720675
[TBL] [Abstract][Full Text] [Related]
36. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
Hua H; Chen W; Shen L; Sheng Q; Teng L
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838
[TBL] [Abstract][Full Text] [Related]
37. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant.
Gerdeman GL; Schechter JB; French ED
Neuropsychopharmacology; 2008 Oct; 33(11):2747-59. PubMed ID: 18059436
[TBL] [Abstract][Full Text] [Related]
38. Rimonabant--a selective CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
[TBL] [Abstract][Full Text] [Related]
39. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats.
Gessa GL; Serra S; Vacca G; Carai MA; Colombo G
Alcohol Alcohol; 2005; 40(1):46-53. PubMed ID: 15582988
[TBL] [Abstract][Full Text] [Related]
40. FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats.
Manwell LA; Satvat E; Lang ST; Allen CP; Leri F; Parker LA
Pharmacol Biochem Behav; 2009 Nov; 94(1):154-62. PubMed ID: 19698735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
